Search Results - "metastasis"
Suggested Topics within your search.
Suggested Topics within your search.
- Neoplasms 5
- drug therapy
- Colorectal Neoplasms 3
- Neovascularization, Physiologic 3
- Vascular Endothelial Growth Factors 3
- complications 3
- therapy 3
- Adjuvant treatment 2
- Cancer 2
- Carcinogenesis 2
- Cell Transformation, Neoplastic 2
- Cellular signal transduction 2
- Drug targeting 2
- G proteins 2
- GTP-Binding Proteins 2
- Immunotherapy 2
- Molecular Targeted Therapy 2
- Precision Medicine 2
- Receptors 2
- Receptors, G-Protein-Coupled 2
- Signal Transduction 2
- metabolism 2
- physiology 2
-
1
G proteins and GPCRs in cancer
Published 2019Table of Contents: “…Contents: G proteins and GPCRs as oncogenes -- G proteins and GPCRs in tumorigenesis -- GPCR signalling -- GPCRs and metastasis -- GPCRs and tumor-induced angiogenesis -- GPCR targeting and immunotherapies.…”
Get full text
Series
Electronic Video -
2
G proteins and GPCRs in cancer
Published 2019Table of Contents: “…Contents: G proteins and GPCRs as oncogenes -- G proteins and GPCRs in tumorigenesis -- GPCR signalling -- GPCRs and metastasis -- GPCRs and tumor-induced angiogenesis -- GPCR targeting and immunotherapies.…”
Get full text
Series
Electronic Video -
3
Changing paradigms in anticancer drug development inhibiting angiogenesis in colorectal cancer /
Published 2009Table of Contents: “…Contents: Targeted therapy for cancer -- Angiogenesis is involved throughout tumour formation, growth and metastasis -- VEGF: molecular characteristics -- VEGF and other signals promote the angiogenic switch in tumours -- Tumour vasculature is abnormal -- VEGF produces immature tortuous vessels dependent on VEGF for survival -- Other features make VEGF an attractive target for anticancer therapy -- RhuMAb VEGF (bevacizumab/Avastin®) -- Significant reduction in microvasculature -- Anti-VEGF antibody improves drug delivery -- Avastin: an anti-VEGF agent for cancer therapy -- Use of Avastin with oxaliplatin-based therapy -- Addition of Avastin to oxaliplatin-based chemotherapy improved best confirmed response -- Study schema and organization.…”
Get full text
Series
Electronic Video -
4
Changing paradigms in anticancer drug development inhibiting angiogenesis in colorectal cancer /
Published 2009Table of Contents: “…Contents: Targeted therapy for cancer -- Angiogenesis is involved throughout tumour formation, growth and metastasis -- VEGF: molecular characteristics -- VEGF and other signals promote the angiogenic switch in tumours -- Tumour vasculature is abnormal -- VEGF produces immature tortuous vessels dependent on VEGF for survival -- Other features make VEGF an attractive target for anticancer therapy -- RhuMAb VEGF (bevacizumab/Avastin®) -- Significant reduction in microvasculature -- Anti-VEGF antibody improves drug delivery -- Avastin: an anti-VEGF agent for cancer therapy -- Use of Avastin with oxaliplatin-based therapy -- Addition of Avastin to oxaliplatin-based chemotherapy improved best confirmed response -- Study schema and organization.…”
Get full text
Series
Electronic Video -
5
Changing paradigms in anticancer drug development inhibiting angiogenesis in colorectal cancer /
Published 2009Table of Contents: “…Contents: Targeted therapy for cancer -- Angiogenesis is involved throughout tumour formation, growth and metastasis -- VEGF: molecular characteristics -- VEGF and other signals promote the angiogenic switch in tumours -- Tumour vasculature is abnormal -- VEGF produces immature tortuous vessels dependent on VEGF for survival -- Other features make VEGF an attractive target for anticancer therapy -- RhuMAb VEGF (bevacizumab/Avastin®) -- Significant reduction in microvasculature -- Anti-VEGF antibody improves drug delivery -- Avastin: an anti-VEGF agent for cancer therapy -- Use of Avastin with oxaliplatin-based therapy -- Addition of Avastin to oxaliplatin-based chemotherapy improved best confirmed response -- Study schema and organization.…”
Get full text
Series
Electronic Video
